Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Psyence Biomedical Ltd (PBM)

Psyence Biomedical Ltd (PBM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
A concept image of a white brain on a blue background surrounded by colorful pills by Tanita_St via Shutterstock
Save This Psychedelic Stock Watchlist After Trump’s Latest Executive Order Barchart - Mon Apr 20, 3:39PM CDT

From manufacturers to high volatility biotechs, these are the mind-bending med stocks our Senior Market Strategist is watching now.

CMPS : 9.46 (+42.04%)
PSIL : 20.72 (+10.48%)
ATAI : 4.90 (+21.59%)
JAZZ : 202.56 (-0.42%)
PBM : 11.30 (+48.68%)
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source GlobeNewswire - Mon Apr 20, 6:42AM CDT

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic...

PBM : 11.30 (+48.68%)
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine GlobeNewswire - Fri Apr 17, 8:15AM CDT

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin...

PBM : 11.30 (+48.68%)
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities GlobeNewswire - Wed Apr 8, 8:15AM CDT

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...

PBM : 11.30 (+48.68%)
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone GlobeNewswire - Wed Mar 11, 8:15AM CDT

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today reinforced how its strategic investment in PsyLabs strengthens its...

PBM : 11.30 (+48.68%)
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial GlobeNewswire - Tue Mar 3, 8:15AM CST

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...

PBM : 11.30 (+48.68%)
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment GlobeNewswire - Fri Feb 20, 4:20PM CST

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”), a biopharmaceutical company advancing nature-derived psilocybin and...

PBM : 11.30 (+48.68%)
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders GlobeNewswire - Tue Feb 17, 8:15AM CST

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”), a biopharmaceutical company advancing nature-derived psilocybin and...

PBM : 11.30 (+48.68%)
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway GlobeNewswire - Fri Feb 13, 5:30PM CST

NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”), a biopharmaceutical company advancing nature-derived psilocybin and...

PBM : 11.30 (+48.68%)
Psyence BioMed Announces Settlement of Shareholder Litigation GlobeNewswire - Wed Feb 11, 8:15AM CST

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (" Psyence BioMed " or the " Company ") today announced that it has entered into a settlement agreement to resolve a...

PBM : 11.30 (+48.68%)

Barchart Exclusives

As Costco Raises Its Dividend More Than 13%, Should You Buy, Sell, or Hold COST Stock? Barchart - Mon Apr 20, 6:30PM CDT
Costco raised its quarterly dividend 13.1% to $1.47 per share. Here's what investors need to know before deciding to buy, sell, or hold COST stock right now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.